Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2025-11-17 Governance Information
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
公司章程
Governance Information Classification · 100% confidence The document is titled as the company's "章程" which translates to "Articles of Association" or "Bylaws." It contains detailed provisions about the company's organization, shareholder rights, board structure, management, financial accounting, meetings, and other governance matters. It references relevant laws and regulations such as the Company Law, Securities Law, and listing rules. The content is a comprehensive governance document that sets out the internal rules and structure of the company rather than financial results, audit opinions, or meeting announcements. It is not a report of financial performance, nor an announcement or transcript. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, confirming it is the governance document itself, not an announcement or summary.
2025-11-17 Chinese
北京观韬律师事务所关于北京康乐卫士生物技术股份有限公司2025年第二次临时股东会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and procedural compliance of a company's 2025 second extraordinary shareholders' meeting. It details the convening, attendance, voting procedures, and results of the meeting. The document does not contain financial statements or performance data, nor is it a report of financial results or management discussion. It is not an announcement of voting results but a legal opinion on the meeting's legality. Therefore, it fits best under Regulatory Filings (RNS), which covers legal and compliance documents that do not fit other categories.
2025-11-17 Chinese
中信证券股份有限公司关于北京康乐卫士生物技术股份有限公司接受控股股东财务资助暨关联交易的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed statement from a securities company (中信证券股份有限公司) acting as a sponsor, providing an opinion on a financial support transaction between a controlling shareholder and the company (北京康乐卫士生物技术股份有限公司). It discusses the terms of a loan, related party transaction details, pricing policies, fairness, decision-making procedures including independent directors' opinions, board and supervisory committee approvals, and compliance with relevant securities regulations. The document is not a full financial report, earnings release, or regulatory filing but rather a formal verification and opinion on a specific related-party financing transaction. This fits the category of Capital/Financing Update (CAP), as it concerns updates on company financing activities and capital structure changes involving related parties. The document length is 2133 characters, which is substantive but not a full annual or interim report. Therefore, the best classification is CAP with high confidence.
2025-10-29 Chinese
董事、高级管理人员持股变动管理制度（2025年第一次修订）
Director's Dealing Classification · 95% confidence The document is titled "董事、高级管理人员持股变动管理制度" which translates to "Management System for Shareholding Changes of Directors and Senior Management." It details rules, procedures, and responsibilities related to the shareholding and trading activities of the company's directors and senior management. It includes sections on information disclosure, prohibited trading periods, account management, and penalties for violations. The document is a formal policy or governance document approved by the company's board on October 30, 2025. It does not contain financial statements, earnings data, or audit information. It is not an announcement of a report but a detailed internal governance regulation concerning directors' dealings in shares. Therefore, the most appropriate classification is "Director's Dealing (DIRS)" as it relates to the management and regulation of share transactions by directors and senior management.
2025-10-29 Chinese
对外担保管理制度（2025年第一次修订）
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the company's external guarantee management system, including its revisions, approval process by the board and shareholders, and detailed procedural and regulatory content. It is not a financial report, earnings release, or audit report. It is a regulatory announcement about internal management policies and governance related to external guarantees. The document is lengthy (5568 characters) and contains substantive content about company policies, but it is not a report of financial results or audit findings. It is not a report publication announcement since it contains the full text of the policy, not just a notice of publication. The content fits best under Regulatory Filings (RNS) as it is a compliance and governance-related announcement that does not fit other specific categories like governance information (CGR) because it is focused on a specific management system rather than overall governance structure. Therefore, the best classification is Regulatory Filings (RNS).
2025-10-29 Chinese
防范控股股东、实际控制人及其他关联方资金占用制度（2025年第一次修订）
Governance Information Classification · 95% confidence The document is a detailed policy document titled 'Prevention of Funds Occupation by Controlling Shareholders, Actual Controllers and Other Related Parties' issued by Beijing Kangle Weishi Biotechnology Co., Ltd. It includes sections on principles, responsibilities, and penalties related to preventing misuse of company funds by controlling shareholders and related parties. The document references company laws, securities laws, and stock exchange listing rules, and it mentions approval by the board and shareholders. It is not a financial report, earnings release, or regulatory filing in the usual sense, nor is it a notice or announcement of a report. It is a governance-related document detailing internal rules and procedures to prevent financial misconduct by controlling shareholders and related parties. Therefore, it fits best under Governance Information (CGR). The document length is 3254 characters, which is relatively short but contains substantive governance content rather than just an announcement or certification. Hence, the classification is CGR with high confidence.
2025-10-29 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.